Major Patent Dispute Erupts as Boehringer Ingelheim Takes China IP Office to Court

Recently, the Supreme People's Court in China commenced hearings on a highly publicized patent dispute involving Boehringer Ingelheim, the German pharmaceutical giant, which is suing the National Intellectual Property Administration (NIPA). The central issue revolves around the patent for its leading diabetes drug, Empagliflozin (marketed as Jardiance in China).

This legal battle highlights the ongoing challenges surrounding the patent rights of innovative drugs, especially concerning their creativity and uniqueness. Empagliflozin is a prominent member of the SGLT2 inhibitor class of medications, renowned for its effectiveness in lowering blood sugar and providing cardiovascular and renal protection. Since its international launch in 2014, the drug's sales have soared, surpassing $10 billion globally by 2023, and it continues to be one of Boehringer Ingelheim's most lucrative products.

In China, Empagliflozin gained approval in 2017 and captured an impressive 90% market share initially. However, a pivotal decision in 2020 by the NIPA invalidated the core compound patent (patent number: CN201310414119.9), claiming that the structure of Empagliflozin lacked inventiveness. This ruling followed a petition by several domestic pharmaceutical companies, including Jiangsu Hengrui and Kelun, which argued that the drug's formulation was based on conventional technology.

Since then, the legal proceedings have seen Boehringer Ingelheim appeal against the NIPA's decision, but it faced initial losses in lower courts. The case is now being heard at the Supreme Court, with the primary focus on the interpretation of Article 22 of the Patent Law concerning "inventiveness."

While the original patent was set to expire in March 2025, the invalidation has led to a surge of generic versions entering the market five years early, significantly impacting the original drug's position.

Empagliflozin's sales figures tell a contrasting story. While it maintains robust global sales, reaching $10.73 billion in 2024, primarily driven by expanding indications for heart failure and chronic kidney disease, its market performance in China has plummeted. In 2023, sales in Chinese public hospitals dropped to just 498 million yuan, with the original brand's market share shrinking from 90% to below 40%.

The competitive landscape is rapidly shifting, with 31 companies now approved to produce generic versions of Empagliflozin in China. These companies are leveraging aggressive pricing strategies to capture market share, which has become increasingly important in light of government procurement policies.

As the legal battle unfolds and the market dynamics continue to evolve, the future of Empagliflozin in China remains uncertain. While the original product boasts brand recognition and established clinical data, generic competitors are poised to erode its market presence. This conflict not only reflects the fierce competition within the diabetes treatment landscape but also underscores the broader implications for pharmaceutical innovation and patent protection in China's evolving healthcare system.